Top

Published in:

01-06-2011

FGF23 in Skeletal Modeling and Remodeling

Authors: Yongbo Lu, Jian Q. Feng

Published in: Current Osteoporosis Reports | Issue 2/2011

Abstract

Fibroblast growth factor 23 (FGF23), a hormone primarily produced in bone cells, targets the kidney to accelerate phosphate excretion into the urine and suppresses vitamin D synthesis, thereby inducing a negative phosphate balance. Excessive serum FGF23 due to hereditary disorders such as hypophosphatemic rickets leads to phosphate wasting and impaired bone mineralization. In contrast, deficiencies in FGF23 are associated with hyperphosphatemia, elevated 1,25(OH)₂D₃, ectopic ossification in soft tissues, and defects in skeletal mineralization. Recent studies of human genetic disorders and genetically engineered mice, as well as the in vitro approaches, have clarified some mysteries in FGF23 regulation and its potential roles in bone modeling and remodeling, which are summarized in this review article.

Yamashita T, Yoshioka M, Itoh N, et al. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277:494–8.PubMedCrossRef

White KE, Evans WE, O'Riordan JLH, et al. ADHR C Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000, 26:345–348.

Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500–5.PubMedCrossRef

Hyp C. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995;1995(11):130–6.

Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310–5.PubMedCrossRef

Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38:1248–50.PubMedCrossRef

Makitie O, Pereira RC, Kaitila I, et al. Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutation. J Bone Miner Res. 2010;25:2165–74.PubMedCrossRef

Koshida R, Yamaguchi H, Yamasaki K, et al. A novel nonsense mutation in the DMP1 gene in a Japanese family with autosomal recessive hypophosphatemic rickets. J Bone Miner Metab. 2010;28:585–90.PubMedCrossRef

Farrow EG, Davis SI, Ward LM, et al. Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets. Bone. 2009;44:287–94.PubMedCrossRef

10.

Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561–8.PubMed

11.

Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23:421–32.PubMedCrossRef

12.

Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006;291:E38–49.PubMedCrossRef

13.

Liu S, Guo R, Simpson LG, et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003;278:37419–26.PubMedCrossRef

14.

Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17:1305–15.PubMedCrossRef

15.

Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280:2543–9.PubMedCrossRef

16.

Ito M, Sakai Y, Furumoto M, et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab. 2005;288:E1101–9.PubMedCrossRef

17.

Perwad F, Azam N, Zhang MY, et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005;146:5358–64.PubMedCrossRef

18.

Burnett SM, Gunawardene SC, Bringhurst FR, et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006;21:1187–96.PubMedCrossRef

19.

Yu X, Sabbagh Y, Davis SI, et al. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone. 2005;36:971–7.PubMedCrossRef

20.

Silver J. Molecular mechanisms of secondary hyperparathyroidism. Nephrol Dial Transplant. 2000;15 Suppl 5:2–7.PubMedCrossRef

21.

•• Lavi-Moshayoff V, Wasserman G, Meir T, et al.: PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010, 299:F882–9. This article provides a convincing data to support a role of PTH in regulation of FGF23.PubMedCrossRef

22.

Saji F, Shiizaki K, Shimada S, et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol. 2009;111:59–66.CrossRef

23.

Gunther T, Chen ZF, Kim J, et al. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature. 2000;406:199–203.PubMedCrossRef

24.

Saji F, Shigematsu T, Sakaguchi T, et al. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol. 2010;299:F1212–7.PubMedCrossRef

25.

Yuan B, Takaiwa M, Clemens TL, et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest. 2008;118:722–34.PubMed

26.

• Aono Y, Yamazaki Y, Yasutake J, et al.: Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 2009, 24:1879–88. This article reported a therapeutic role of anti-FGF23 antibodies in hypophosphatemic rickets mouse model.PubMedCrossRef

27.

•• Zhang R, Lu Y, Ye L, et al.: Unique roles of phosphorus in endochondral bone formation and osteocyte maturation. J Bone Miner Res. 2011, in press. This article reported a severe defect of skeleton modeling/remodeling in Dmp1 null mice. It also proposes a model to explain why and how FGF23 is abnormally expressed in Dmp1 null osteocytes.

28.

• Lu Y, Yuan B, Qin C, et al.: The biological function of DMP1 in osteocyte maturation is mediated by its 57 kDa C-terminal fragment. J Bone Miner Res. 2011, in press. This article provided critical evidence that the 57-kDa C-terminal fragment of DMP1 fully rescues Dmp1-null phenotype.

29.

Benet-Pages A, Lorenz-Depiereux B, Zischka H, et al. FGF23 is processed by proprotein convertases but not by PHEX. Bone. 2004;35:455–62.PubMedCrossRef

30.

Guo R, Liu S, Spurney RF. Quarles LD Analysis of recombinant Phex: an endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab. 2001;281:E837–47.PubMed

31.

Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002;143:3179–82.PubMedCrossRef

32.

Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314:409–14.PubMedCrossRef

33.

Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145:3087–94.PubMedCrossRef

34.

Bai X, Miao D, Li J, et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004;145:5269–79.PubMedCrossRef

35.

• Aono Y, Hasegawa H, Yamazaki Y, et al.: Anti-FGF23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res. 2011, in press. This article provided critical evidence to show a phosphate-independent function of FGF23 on bone using double mutant mice deficient in Fgf23 and Napi2a genes.

36.

Hayashibara T, Hiraga T, Sugita A, et al. Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions. J Bone Miner Res. 2007;22:1743–51.PubMedCrossRef

37.

Murshed M, Harmey D, Millan JL, et al. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 2005;19:1093–104.PubMedCrossRef

38.

Sitara D, Razzaque MS, St-Arnaud R, et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol. 2006;169:2161–70.PubMedCrossRef

39.

Hesse M, Frohlich LF, Zeitz U, et al. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol. 2007;26:75–84.PubMedCrossRef

40.

• Wang H, Yoshiko Y, Yamamoto R, et al.: Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008, 23:939–48. This article documents a direct role of FGF23 in bone cells in vitro.PubMedCrossRef

41.

Rice DP, Aberg T, Chan Y, et al. Integration of FGF and TWIST in calvarial bone and suture development. Development. 2000;127:1845–55.PubMed

42.

Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51.PubMedCrossRef

43.

Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281:6120–3.PubMedCrossRef

44.

• Sitara D, Kim S, Razzaque MS, et al.: Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 2008, 4:e1000154. This article provided critical evidence to show a phosphate-independent function of FGF23 on bone using double mutant mice deficient in Fgf23 and Napi2a genes.PubMedCrossRef

45.

Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007;18:2116–24.PubMedCrossRef

Title: FGF23 in Skeletal Modeling and Remodeling
Authors: Yongbo Lu
Jian Q. Feng
Publication date: 01-06-2011
Publisher: Current Science Inc.
Published in: Current Osteoporosis Reports / Issue 2/2011
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-011-0053-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

FGF23 in Skeletal Modeling and Remodeling

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Effects of Nutrition and Alcohol Consumption on Bone Loss

FoxOs: Unifying Links Between Oxidative Stress and Skeletal Homeostasis

Bone Structural Components Regulating Sites of Tumor Metastasis

Role of Altered Signal Transduction in Heterotopic Ossification and Fibrodysplasia Ossificans Progressiva

The Role of Bone Marrow and Visceral Fat on Bone Metabolism

Role of Endocrine and Paracrine Factors in the Adaptation of Bone to Mechanical Loading